Shanghai Bao Pharmaceuticals Co., Ltd. (BAO PHARMA-B) disclosed on 13 July 2026 that it bought back 101,700 H-shares on the Hong Kong Stock Exchange. The transaction, executed under the company’s existing repurchase mandate, was completed at prices between HK$19.20 and HK$20.24 per share, with a volume-weighted average cost of HK$19.61 per share, bringing the total cash outlay to HK$1.99 million.

Following the repurchase, the number of issued shares (excluding treasury shares) decreased to 153.49 million, down from 153.59 million prior to the transaction. Treasury shares increased to 834,900, while the company’s total issued share count, including treasury shares, remained unchanged at 154.33 million.

The shares were repurchased under the authority granted by shareholders on 26 May 2026, which allows the company to buy back up to 15.43 million shares. Cumulative repurchases under this mandate now stand at 834,900 shares, representing 0.54% of the issued share capital as of the mandate date.

In line with Hong Kong listing rules, BAO PHARMA-B is subject to a moratorium on issuing new shares or disposing of treasury shares until 12 August 2026. The board confirmed that the repurchase was duly authorised and executed in full compliance with all applicable regulations.